Level C· Early human research exploring benefitsCase Report / SeriesEurope PMC

Lipotransfer provides effective soft tissue replacement for acquired partial lipodystrophy

Jeon FHK., Griffin M., Frosdick C., Butler PEM.

Case Report / Series on Face & Skin, published in BMJ Case Rep (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
BMJ Case Rep (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32404319
PMCID
PMC7228454
DOI
10.1136/bcr-2019-232601
Citations
4

Abstract (original English)

We present a 48-year-old female patient who presented with features consistent with acquired partial lipodystrophy (APL) also known as 'Barraquer-Simons syndrome'. It is a rare disease characterised by a gradual and progressive onset of lipoatrophy limited to the face, neck, upper limbs, thorax and abdomen and sparing the lower extremities. The resultant physical appearance can have significant psychosocial sequelae, further compounded by misdiagnosis and delay in recognition and management. Treatment is aimed at surgical correction of soft tissue destruction. Autologous fat transfer is an established plastic and reconstructive procedure that is safe and minimally invasive and can be used to reconstruct a variety of soft tissue defects and has shown to be an effective treatment modality in patients with APL.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
FaceAdipose TissueHumansLipodystrophyMiddle AgedFemaleAutograftsPlastic Surgery Procedures

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research